iTeos Therapeutics, Inc.iTeos Therapeutics, Inc.iTeos Therapeutics, Inc.

iTeos Therapeutics, Inc.

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪626.37 M‬USD
−3.78USD
‪−112.64 M‬USD
‪12.60 M‬USD
‪27.62 M‬
Beta (1Y)
2.06

About iTeos Therapeutics, Inc.

CEO
Michel Detheux
Headquarters
Watertown
Employees (FY)
157
Founded
2012
FIGI
BBG00VPNFSJ5
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of ITOS is 17.18 USD — it has decreased by 0.95% in the past 24 hours. Watch iTeos Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange iTeos Therapeutics, Inc. stocks are traded under the ticker ITOS.
ITOS stock has fallen by 3.40% compared to the previous week, the month change is a 59.18% rise, over the last year iTeos Therapeutics, Inc. has showed a 4.92% increase.
We've gathered analysts' opinions on iTeos Therapeutics, Inc. future price: according to them, ITOS price has a max estimate of 46.00 USD and a min estimate of 21.00 USD. Watch ITOS chart and read a more detailed iTeos Therapeutics, Inc. stock forecast: see what analysts think of iTeos Therapeutics, Inc. and suggest that you do with its stocks.
ITOS reached its all-time high on Jan 3, 2022 with the price of 52.43 USD, and its all-time low was 8.20 USD and was reached on Oct 12, 2023. View more price dynamics on ITOS chart.
See other stocks reaching their highest and lowest prices.
ITOS stock is 2.07% volatile and has beta coefficient of 2.06. Track iTeos Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is iTeos Therapeutics, Inc. there?
Today iTeos Therapeutics, Inc. has the market capitalization of ‪626.37 M‬, it has decreased by 1.14% over the last week.
Yes, you can track iTeos Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
iTeos Therapeutics, Inc. is going to release the next earnings report on Aug 7, 2024. Keep track of upcoming events with our Earnings Calendar.
ITOS earnings for the last quarter are −1.07 USD per share, whereas the estimation was −0.98 USD resulting in a −8.91% surprise. The estimated earnings for the next quarter are −1.00 USD per share. See more details about iTeos Therapeutics, Inc. earnings.
iTeos Therapeutics, Inc. revenue for the last quarter amounts to 0 USD despite the estimated figure of 0 USD. In the next quarter revenue is expected to reach ‪1.00 M‬ USD.
ITOS net income for the last quarter is ‪−38.22 M‬ USD, while the quarter before that showed ‪−30.55 M‬ USD of net income which accounts for −25.09% change. Track more iTeos Therapeutics, Inc. financial stats to get the full picture.
No, ITOS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 30, 2024, the company has 157.00 employees. See our rating of the largest employees — is iTeos Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. iTeos Therapeutics, Inc. EBITDA is ‪−172.32 M‬ USD, and current EBITDA margin is ‪−1.19 K‬%. See more stats in iTeos Therapeutics, Inc. financial statements.
Like other stocks, ITOS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade iTeos Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So iTeos Therapeutics, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating iTeos Therapeutics, Inc. stock shows the buy signal. See more of iTeos Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.